<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00302081</url>
  </required_header>
  <id_info>
    <org_study_id>P03548</org_study_id>
    <nct_id>NCT00302081</nct_id>
  </id_info>
  <brief_title>Three Regimens of PegIntron Plus Ribavirin in Previously Untreated Chronic Hepatitis C, Genotype 2 or 3 (Study P03548)</brief_title>
  <official_title>Comparison of Three Regimens of PEG-Intron and Ribavirin in the Treatment of Chronic Hepatitis C, Genotype 2 or 3, in Previously Untreated Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Integrated Therapeutics Group</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open-label, multinational study designed to evaluate the &quot;standard&quot;
      regimen, PegIntron 1.5 µg/kg subcutaneously once weekly plus ribavirin 800-1200 mg daily [Arm
      PEG2b 1.5/R (24 weeks)], compared to a lower dose regimen, PegIntron 1.0 µg/kg subcutaneously
      once weekly plus ribavirin 800-1200 mg daily [Arm PEG2b 1.0/R (24 weeks)], using a 24 week
      treatment duration for both arms. Additionally, the study examined the efficacy of reduced
      treatment duration: PegIntron 1.5 µg/kg subcutaneously once weekly plus ribavirin 800-1200 mg
      for 16 weeks [Arm PEG2b 1.5/R (16 weeks)] .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, open-label, multinational study designed to evaluate the &quot;standard&quot;
      regimen, PegIntron 1.5 µg/kg subcutaneously once weekly plus ribavirin 800-1200 mg daily [Arm
      PEG2b 1.5/R (24 weeks)], compared to a lower dose regimen, PegIntron 1.0 µg/kg subcutaneously
      once weekly plus ribavirin 800-1200 mg daily [Arm PEG2b 1.0/R (24 weeks)], using a 24 week
      treatment duration for both arms. Additionally, the study examined the efficacy of reduced
      treatment duration: PegIntron 1.5 µg/kg subcutaneously once weekly plus ribavirin 800-1200 mg
      for 16 weeks [Arm PEG2b 1.5/R (16 weeks)].
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2003</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Participants Who Achieve a Sustained Virologic Response (SVR)</measure>
    <time_frame>24-week treatment duration for Arms [Peg2b 1.5/R(24 weeks)] and [PEG2b 1.0/R(24 weeks]); 16-week treatment duration for Arm [PEG2b 1.5/R(16 weeks]. Follow-up of 24 weeks for each arm.</time_frame>
    <description>A sustained virologic response is defined as undetectable hepatitis C virus ribonucleic acid [HCV-RNA] 24 weeks post-treatment. Serum HCV-RNA is measured by HCV-PCR in local laboratories. HCV-RNA below the limit of detection is considered undetectable.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Virologic Response Rates at the End of Therapy. Biochemical Responses as Determined by ALT and AST Levels at the End of Treatment and at the End of Follow up.</measure>
    <time_frame>End of treatment: 24 weeks for arms [PEG2b 1.5/R (24 weeks)] and [PEG2b 1.0/R (24 weeks)]; 16 weeks for arm [PEG2b 1.5/R (16 weeks)]. Follow-up of 24 weeks for each arm.</time_frame>
    <description>Virologic response is defined as undetectable hepatitis C virus ribonucleic acid (HCV-RNA) in the serum. A blood test is used to measure the level of ALT and AST. ALT response was defined as ALT&lt;40 IU/L (international units per liter).
This was not a prespecified key secondary outcome.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">696</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>PEG2b 1.5/R (24 weeks)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PegIntron (peginterferon alfa-2b; SCH 54031) 1.5 mcg/kg QW SC plus ribavirin (SCH 18908) 800-1200 mg daily for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEG 2b 1.0/R (24 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PegIntron (peginterferon alfa-2b; SCH 54031) 1.0 mcg/kg QW SC plus ribavirin (SCH 18908) 800-1200 mg/day for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEG2b 1.5/R (16 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PegIntron (peginterferon alfa-2b; SCH 54031) 1.5 mcg/kg QW SC plus ribavirin (SCH 18908) 800-1200 mg/day for 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>peginterferon alfa-2b (SCH 54031)</intervention_name>
    <description>1.5 mcg/kg QW SC for 24 weeks</description>
    <arm_group_label>PEG2b 1.5/R (24 weeks)</arm_group_label>
    <other_name>PegIntron (SCH 54031)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>peginterferon alfa-2b (SCH 54031)</intervention_name>
    <description>1.0 mcg/kg QW SC for 24 weeks</description>
    <arm_group_label>PEG 2b 1.0/R (24 weeks)</arm_group_label>
    <other_name>PegIntron (SCH 54031)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>peginterferon alfa-2b (SCH 54031)</intervention_name>
    <description>1.5 mcg/kg QW SC for 16 weeks</description>
    <arm_group_label>PEG2b 1.5/R (16 weeks)</arm_group_label>
    <other_name>PegIntron (SCH 54031)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ribavirin (SCH 18908)</intervention_name>
    <description>800-1200 mg daily for 24 weeks</description>
    <arm_group_label>PEG2b 1.5/R (24 weeks)</arm_group_label>
    <arm_group_label>PEG 2b 1.0/R (24 weeks)</arm_group_label>
    <other_name>REBETOL (SCH 18908)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ribavirin (SCH 18908)</intervention_name>
    <description>800-1200 mg daily for 16 weeks</description>
    <arm_group_label>PEG2b 1.5/R (16 weeks)</arm_group_label>
    <other_name>REBETOL (SCH 18908)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        The subject must meet ALL of the criteria listed below for entry into the study:

          -  Hemoglobin &gt;= 11 g/dL (females); &gt;= 12 g/dL (males)

          -  Platelet count &gt;= 100,000/mm^3

          -  Neutrophil count &gt;= 1,500/mm^3

          -  Adult male or female chronic hepatitis C (CHC) patients (HCV-RNA-positive in serum)
             with compensated liver disease (Child-Pugh Score &lt;7) and indication for treatment
             according on current consensus guidelines (1. NIH Consensus Conference on the
             Management of Hepatitis C, 2002; 2. German Consensus Conference on Hepatitis B and C,
             published in Z Gastro 2004; 42 (8): 677-730).

          -  &gt;= 18 to =&lt; 70 years of age

          -  At least one abnormal ALT value in the last year

          -  HCV genotype 2 or 3

          -  Not previously treated with any interferon or ribavirin alone or in combination

          -  TSH level must be within normal limits

          -  At the Screen Visit, glucose must be 70-140 mg/dL. Results between 116-140 mg/dL
             require repeat fasting glucose to be less than140 mg/dL and HbA1C less than or equal
             to 8.5%. HbA1C must be less than or equal to 8.5% in diabetic subjects (whether on
             medication or diet controlled).

          -  Female subjects cannot be pregnant or breastfeeding and must be either postmenopausal,
             surgically sterile or using 2 methods of birth control. While abstinence from sexual
             activity is the only certain method to prevent pregnancy, female patients of
             childbearing potential who are or who anticipate the possibility of becoming sexually
             active with a male partner must use a combination of the following 2 methods:
             (1)contraceptive pill or IUD or depot hormonal preparation (ring, injection implant);
             and (2) a barrier method of contraception such as diaphragm, sponge with spermicide,
             condom, or a method of birth control considered acceptable by the study physician.
             Contraceptive measures will be reviewed with female subjects at each visit. Dual
             methods of contraception must be used for 6 months after treatment discontinuation.

          -  Sexually active male subjects must be practicing acceptable methods of contraception
             (vasectomy, use of condom plus spermicide, monogamous relationship with a female
             partner who practices an acceptable method of contraception) during the treatment
             period and for 7 months after stopping treatment

          -  Subjects must be willing to give written informed consent and able to adhere to dosing
             and visit schedules.

          -  Confirmation by the principal investigator or a sub-investigator that sexually active
             females of childbearing potential are practicing adequate contraception.

          -  A serum pregnancy test obtained at Screen Visit prior to the initiation of treatment
             must be negative

          -  Confirmation by the principal investigator or a sub-investigator that sexually active
             male subjects are practicing a method of contraception considered acceptable
             (vasectomy, condom plus spermicide, plus relationship with a female partner who
             practices an acceptable method of contraception). Contraception must be used during
             the treatment period and for seven months (or 6 months, according to local label)
             after the completion of therapy, including condom use by male subjects with pregnant
             partners.

          -  For subjects with a history of hypertension or diabetes, written clearance from an
             ophthalmologist has to be obtained prior to treatment start

        Exclusion Criteria:

          -  Patients younger than 18 years

          -  Patients older than 70 years of age.

          -  Positive Anti-HIV antibodies

          -  Positive HBsAg antibodies

          -  Patients with severe renal dysfunction or creatinine clearance &lt; 50 mL/min must not be
             treated with PEG-Intron -Rebetol

          -  Pregnant women, women who plan to become pregnant, male subjects whose partner wants
             to become pregnant, and breastfeeding women.

          -  Suspected hypersensitivity to any interferon or ribavirin product.

          -  Subject has used any investigational product within 30 days prior to enrollment

          -  Subject is participating in any other clinical study

          -  Any cause of liver disease other than chronic hepatitis C, including but not limited
             to:

               -  Hemochromatosis

               -  Alpha-1 antitrypsin deficiency

               -  Wilson's disease

               -  Autoimmune hepatitis

               -  Alcoholic liver disease

               -  Non-alcoholic steatohepatitis (NASH)

               -  Drug-related liver disease

          -  Active malignant disease or suspicion or history of malignant disease within five
             previous years (except for adequately treated basal cell carcinoma)

          -  Known coagulation diseases such as hemophilia; hemoglobin diseases (e.g. thalassemia)

          -  Known G6PD deficiency

          -  Evidence of advanced liver disease such as history or presence of ascites, bleeding
             varices, or hepatic encephalopathy.

          -  Subjects with organ transplants, except for corneal or hair transplant.

          -  Any known preexisting medical condition that could interfere with the subject's
             participation in and completion of study, such as:

               -  Preexisting psychiatric condition, especially moderate to severe depression, or a
                  history of severe psychiatric disorder, such as psychosis, suicidal ideation, or
                  suicide attempts. Severe depression includes the following: hospitalization for
                  depression; electroconvulsive therapy for depression; or depression causing a
                  prolonged absence from work or significantly altering daily functions. Subjects
                  with mild depression may be considered for entry into the study provided that a
                  pre-treatment assessment demonstrates that the subject's emotional status is
                  clinically stable, in which case a management plan must be formulated for the
                  subject; this management plan will become a part of the subject's medical record.

               -  Craniocerebral trauma which is not a concussion or active seizure disorders
                  requiring medication.

               -  Clinically significant ECG abnormalities and/or cardiovascular dysfunction within
                  6 previous months (e.g., angina, congestive heart failure, recent myocardial
                  infarction, or significant arrhythmia).

               -  Chronic lung disease (e.g., chronic obstructive lung disease)

               -  Poorly controlled diabetes mellitus

               -  Immune-mediated disease (e.g., inflammatory bowel disease [Crohn's disease,
                  ulcerative colitis], idiopathic thrombocytopenic purpura, systemic lupus
                  erythematosus, autoimmune hemolytic anemia, scleroderma, severe psoriasis)

               -  Clinical gout

          -  Subject is or was a substance abuser, such as alcohol (80 gm/day or more), methadone,
             IV, oral or inhaled drugs. To be considered for inclusion into the protocol, the
             subject must have abstained and agree to abstain from using any of the above for at
             least 6 months. Subjects treated with buprenorphine (Subutex) who have been stable for
             6 months may be included

          -  Any other condition that, in the investigator's opinion, could determine that
             subject's participation in the study is not indicated or could interfere with the
             subject's participation in and completion of study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>India</country>
    <country>Indonesia</country>
    <country>Israel</country>
    <country>Poland</country>
    <country>Singapore</country>
    <country>Thailand</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2006</study_first_submitted>
  <study_first_submitted_qc>March 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2006</study_first_posted>
  <results_first_submitted>April 29, 2009</results_first_submitted>
  <results_first_submitted_qc>June 24, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 11, 2009</results_first_posted>
  <last_update_submitted>March 8, 2017</last_update_submitted>
  <last_update_submitted_qc>March 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C, Chronic</keyword>
  <keyword>Genotype 2 and Genotype 3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>696 subjects were randomized. 14 subjects never received any study drug and, therefore, were excluded from the Intent to Treat (ITT) population. ITT population consisted of 682 subjects.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PEG2b 1.5/R (24 Weeks)</title>
          <description>PegIntron (peginterferon alfa-2b; SCH 54031) 1.5 mcg/kg QW SC plus ribavirin (SCH 18908) 800-1200 mg daily for 24 weeks</description>
        </group>
        <group group_id="P2">
          <title>PEG2b 1.0/R (24 Weeks)</title>
          <description>PegIntron (peginterferon alfa-2b; SCH 54031) 1.0 mcg/kg QW SC plus ribavirin (SCH 18908) 800-1200 mg/day for 24 weeks</description>
        </group>
        <group group_id="P3">
          <title>PEG2b 1.5/R (16 Weeks)</title>
          <description>PegIntron (peginterferon alfa-2b; SCH 54031) 1.5 mcg/kg QW SC plus ribavirin (SCH 18908) 800-1200 mg/day for 16 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="237"/>
                <participants group_id="P2" count="229"/>
                <participants group_id="P3" count="230"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="181"/>
                <participants group_id="P2" count="186"/>
                <participants group_id="P3" count="178"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="52"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PEG2b 1.5/R (24 Weeks)</title>
          <description>PegIntron (peginterferon alfa-2b; SCH 54031) 1.5 mcg/kg QW SC plus ribavirin (SCH 18908) 800-1200 mg daily for 24 weeks</description>
        </group>
        <group group_id="B2">
          <title>PEG2b 1.0/R (24 Weeks)</title>
          <description>PegIntron (peginterferon alfa-2b; SCH 54031) 1.0 mcg/kg QW SC plus ribavirin (SCH 18908) 800-1200 mg/day for 24 weeks</description>
        </group>
        <group group_id="B3">
          <title>PEG2b 1.5/R (16 Weeks)</title>
          <description>PegIntron (peginterferon alfa-2b; SCH 54031) 1.5 mcg/kg QW SC plus ribavirin (SCH 18908) 800-1200 mg/day for 16 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="230"/>
            <count group_id="B2" value="224"/>
            <count group_id="B3" value="228"/>
            <count group_id="B4" value="682"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.8" spread="10.2"/>
                    <measurement group_id="B2" value="39.9" spread="11.2"/>
                    <measurement group_id="B3" value="39.7" spread="11.1"/>
                    <measurement group_id="B4" value="39.5" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="80"/>
                    <measurement group_id="B4" value="249"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                    <measurement group_id="B2" value="146"/>
                    <measurement group_id="B3" value="148"/>
                    <measurement group_id="B4" value="433"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of Participants Who Achieve a Sustained Virologic Response (SVR)</title>
        <description>A sustained virologic response is defined as undetectable hepatitis C virus ribonucleic acid [HCV-RNA] 24 weeks post-treatment. Serum HCV-RNA is measured by HCV-PCR in local laboratories. HCV-RNA below the limit of detection is considered undetectable.</description>
        <time_frame>24-week treatment duration for Arms [Peg2b 1.5/R(24 weeks)] and [PEG2b 1.0/R(24 weeks]); 16-week treatment duration for Arm [PEG2b 1.5/R(16 weeks]. Follow-up of 24 weeks for each arm.</time_frame>
        <population>Intent-to-Treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>PEG2b 1.5/R (24 Weeks)</title>
            <description>PegIntron (peginterferon alfa-2b; SCH 54031) 1.5 mcg/kg QW SC plus ribavirin (SCH 18908) 800-1200 mg daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>PEG2b 1.0/R (24 Weeks)</title>
            <description>PegIntron (peginterferon alfa-2b; SCH 54031) 1.0 mcg/kg QW SC plus ribavirin (SCH 18908) 800-1200 mg/day for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>PEG2b 1.5/R (16 Weeks)</title>
            <description>PegIntron (peginterferon alfa-2b; SCH 54031) 1.5 mcg/kg QW SC plus ribavirin (SCH 18908) 800-1200 mg/day for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants Who Achieve a Sustained Virologic Response (SVR)</title>
          <description>A sustained virologic response is defined as undetectable hepatitis C virus ribonucleic acid [HCV-RNA] 24 weeks post-treatment. Serum HCV-RNA is measured by HCV-PCR in local laboratories. HCV-RNA below the limit of detection is considered undetectable.</description>
          <population>Intent-to-Treat (ITT) population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="224"/>
                <count group_id="O3" value="228"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153"/>
                    <measurement group_id="O2" value="144"/>
                    <measurement group_id="O3" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This is an evaluation of the effect of the peginterferon alfa-2b dose (1.0 vs 1.5 micrograms/kg/week) on the primary outcome measure.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority for SVR was concluded if the lower limit of the one-sided 95% CI was greater than -10%. Otherwise, noninferiority was concluded for both dose and treatment duration comparisons if the lower limits of the two-sided 95% CIs were greater than -10%.</non_inferiority_desc>
            <p_value>0.041</p_value>
            <p_value_desc>The Hochberg procedure was used to adjust for the multiple comparisons ([PEG2b 1.0/R(24 weeks)] - [PEG2b 1.5/R(24 weeks]) and ([PEG2b 1.5/R(16 weeks)]-[PEG2b 1.5/R(24 weeks)]).</p_value_desc>
            <method>z-test (non-inferiority margin=-0.1)</method>
            <method_desc>SVR rates are 0.665 (153/230 subjects) in the 1.5-dose group and 0.643 (144/224 subjects) in the 1.0-dose group, for a risk difference of -0.02.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.10</ci_lower_limit>
            <ci_upper_limit>1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This is an evaluation of the effect of treatment duration (24 weeks vs 16 weeks) on the primary outcome measure.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority for SVR was concluded if the lower limit of the one-sided 95% CI was greater than -10%. Otherwise, noninferiority was concluded for both dose and treatment duration comparisons if the lower limits of the two-sided 95% CIs were greater than -10%.</non_inferiority_desc>
            <p_value>0.495</p_value>
            <p_value_desc>The Hochberg procedure was used to adjust for the multiple comparisons ([PEG2b 1.0/R(24 weeks)] - [PEG2b 1.5/R(24 weeks]) and ([PEG2b 1.5/R(16 weeks]-[PEG2b 1.5/R(24 weeks]).</p_value_desc>
            <method>z-test (non-inferiority margin=-0.1)</method>
            <method_desc>SVR rates are 0.665 (153/230 subjects) in the 24-week group and 0.566 (129/228 subjects) in the 16-week group, for a risk difference of -0.10.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.17</ci_lower_limit>
            <ci_upper_limit>1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response Rates at the End of Therapy. Biochemical Responses as Determined by ALT and AST Levels at the End of Treatment and at the End of Follow up.</title>
        <description>Virologic response is defined as undetectable hepatitis C virus ribonucleic acid (HCV-RNA) in the serum. A blood test is used to measure the level of ALT and AST. ALT response was defined as ALT&lt;40 IU/L (international units per liter).
This was not a prespecified key secondary outcome.</description>
        <time_frame>End of treatment: 24 weeks for arms [PEG2b 1.5/R (24 weeks)] and [PEG2b 1.0/R (24 weeks)]; 16 weeks for arm [PEG2b 1.5/R (16 weeks)]. Follow-up of 24 weeks for each arm.</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>PEG2b 1.5/R*(24 Weeks)</title>
        </group>
        <group group_id="E2">
          <title>PEG2b 1.0/R*(24 Weeks)</title>
        </group>
        <group group_id="E3">
          <title>PEG2b 1.5/R*(16 Weeks)</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>PALPITATIONS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>AMAUROSIS FUGAX</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>RETINAL DETACHMENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>VISUAL DISTURBANCE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ASCITES</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>HERNIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>HEPATIC FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>JAUNDICE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ABSCESS LIMB</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>CYSTITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>PULMONARY TUBERCULOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ANKLE FRACTURE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>LIGAMENT RUPTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>THERMAL BURN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BLOOD PRESSURE INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RHABDOMYOLYSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>CERVIX CARCINOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>PANCREATIC CARCINOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CEREBRAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>COMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>DEPRESSED LEVEL OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>PREGNANCY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>AGGRESSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>AGITATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>ALCOHOL WITHDRAWAL SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>ANGER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>DELIRIUM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>DEPRESSED MOOD</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>NERVOUSNESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>PERSECUTORY DELUSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>PSYCHOTIC DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>SUICIDAL IDEATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>SUICIDE ATTEMPT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>NEPHROPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PSORIASIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>SKIN LESION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>PREGNANCY OF PARTNER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="196" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="187" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="201" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="27" subjects_affected="22" subjects_at_risk="230"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="224"/>
                <counts group_id="E3" events="26" subjects_affected="25" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="230"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="224"/>
                <counts group_id="E3" events="22" subjects_affected="22" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="230"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="224"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="230"/>
                <counts group_id="E2" events="21" subjects_affected="18" subjects_at_risk="224"/>
                <counts group_id="E3" events="13" subjects_affected="9" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="28" subjects_affected="22" subjects_at_risk="230"/>
                <counts group_id="E2" events="28" subjects_affected="27" subjects_at_risk="224"/>
                <counts group_id="E3" events="18" subjects_affected="16" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>DRY MOUTH</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="230"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="224"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="230"/>
                <counts group_id="E2" events="25" subjects_affected="20" subjects_at_risk="224"/>
                <counts group_id="E3" events="18" subjects_affected="14" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="32" subjects_affected="27" subjects_at_risk="230"/>
                <counts group_id="E2" events="29" subjects_affected="26" subjects_at_risk="224"/>
                <counts group_id="E3" events="34" subjects_affected="31" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="230"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="224"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" events="74" subjects_affected="44" subjects_at_risk="230"/>
                <counts group_id="E2" events="75" subjects_affected="62" subjects_at_risk="224"/>
                <counts group_id="E3" events="63" subjects_affected="45" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="230"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="224"/>
                <counts group_id="E3" events="17" subjects_affected="16" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="64" subjects_affected="52" subjects_at_risk="230"/>
                <counts group_id="E2" events="57" subjects_affected="50" subjects_at_risk="224"/>
                <counts group_id="E3" events="43" subjects_affected="36" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>INFLUENZA LIKE ILLNESS</sub_title>
                <counts group_id="E1" events="35" subjects_affected="29" subjects_at_risk="230"/>
                <counts group_id="E2" events="24" subjects_affected="21" subjects_at_risk="224"/>
                <counts group_id="E3" events="31" subjects_affected="23" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>INJECTION SITE ERYTHEMA</sub_title>
                <counts group_id="E1" events="27" subjects_affected="26" subjects_at_risk="230"/>
                <counts group_id="E2" events="40" subjects_affected="31" subjects_at_risk="224"/>
                <counts group_id="E3" events="18" subjects_affected="17" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>IRRITABILITY</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="230"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="224"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" events="56" subjects_affected="17" subjects_at_risk="230"/>
                <counts group_id="E2" events="55" subjects_affected="13" subjects_at_risk="224"/>
                <counts group_id="E3" events="53" subjects_affected="13" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="328" subjects_affected="87" subjects_at_risk="230"/>
                <counts group_id="E2" events="300" subjects_affected="83" subjects_at_risk="224"/>
                <counts group_id="E3" events="296" subjects_affected="101" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>HAEMOGLOBIN DECREASED</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="230"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="224"/>
                <counts group_id="E3" events="14" subjects_affected="11" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="230"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="224"/>
                <counts group_id="E3" events="31" subjects_affected="31" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ANOREXIA</sub_title>
                <counts group_id="E1" events="32" subjects_affected="28" subjects_at_risk="230"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="224"/>
                <counts group_id="E3" events="23" subjects_affected="22" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="230"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="224"/>
                <counts group_id="E3" events="13" subjects_affected="12" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="27" subjects_affected="25" subjects_at_risk="230"/>
                <counts group_id="E2" events="22" subjects_affected="17" subjects_at_risk="224"/>
                <counts group_id="E3" events="27" subjects_affected="24" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="230"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="224"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" events="64" subjects_affected="35" subjects_at_risk="230"/>
                <counts group_id="E2" events="31" subjects_affected="27" subjects_at_risk="224"/>
                <counts group_id="E3" events="35" subjects_affected="34" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="230"/>
                <counts group_id="E2" events="22" subjects_affected="16" subjects_at_risk="224"/>
                <counts group_id="E3" events="16" subjects_affected="15" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DISTURBANCE IN ATTENTION</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="230"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="224"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="230"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="224"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="74" subjects_affected="52" subjects_at_risk="230"/>
                <counts group_id="E2" events="98" subjects_affected="57" subjects_at_risk="224"/>
                <counts group_id="E3" events="78" subjects_affected="58" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>DEPRESSED MOOD</sub_title>
                <counts group_id="E1" events="26" subjects_affected="25" subjects_at_risk="230"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="224"/>
                <counts group_id="E3" events="19" subjects_affected="19" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="230"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="224"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="230"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="224"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>SLEEP DISORDER</sub_title>
                <counts group_id="E1" events="22" subjects_affected="19" subjects_at_risk="230"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="224"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="21" subjects_affected="19" subjects_at_risk="230"/>
                <counts group_id="E2" events="28" subjects_affected="22" subjects_at_risk="224"/>
                <counts group_id="E3" events="23" subjects_affected="22" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="230"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="224"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" events="49" subjects_affected="48" subjects_at_risk="230"/>
                <counts group_id="E2" events="37" subjects_affected="36" subjects_at_risk="224"/>
                <counts group_id="E3" events="31" subjects_affected="31" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>DRY SKIN</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="230"/>
                <counts group_id="E2" events="26" subjects_affected="25" subjects_at_risk="224"/>
                <counts group_id="E3" events="16" subjects_affected="15" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" events="35" subjects_affected="29" subjects_at_risk="230"/>
                <counts group_id="E2" events="49" subjects_affected="44" subjects_at_risk="224"/>
                <counts group_id="E3" events="25" subjects_affected="23" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="230"/>
                <counts group_id="E2" events="18" subjects_affected="15" subjects_at_risk="224"/>
                <counts group_id="E3" events="14" subjects_affected="12" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

